Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder
Key facts
- Who runs it
- University of Texas at Austin
- Where
- Austin, United StatesSee the site
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 150 people, planned
- Started
- 15 Jan 2020
- Ended
- May 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CBD Isolate
- CBD Broad Spectrum
- Placebo oil
- Record updated
- 22 November 2023
- Why it stopped
- Suspended (The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder
- Age 18 or older
- Fluent in English
- Has access to the internet
- Willingness to provide signed informed consent
- Willingness to refrain from all non-study cannabis use during the study period
Who cannot take part
- History of a suicide attempt within the past 6 months
- History of psychosis within the past 6 months
- History of current alcohol or substance use disorder within the past month
- History of adverse reaction to CBD oil or other CBD products
- Allergy to coconut oil
- Any medical problems that would preclude participating in the study
Where in United States
- Laboratory for the Study of Anxiety Disorders, University of Texas at AustinAustin, United States
About the trial
What the trial wants to find out
The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of post-traumatic stress disorder using a rigorous double-blind randomized clinical trial methodology. Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) CBD-Broad Spectrum; (c) Placebo oil.
Read full original descriptionShow less
We predict that patients receiving CBD isolate or CBD Broad Spectrum will show significantly greater improvements in PTSD symptoms and functional impairment at the posttreatment and one-month follow-up relative to patients receiving placebo oil. Additionally, we expect that patients receiving CBD Broad Spectrum will show significantly greater improvements relative to patients receiving CBD Isolate.
The 3 groups in the trial
- CBD IsolateExisting treatment, for comparison
300 mg/day of CBD isolate
- CBD Broad SpectrumExisting treatment, for comparison
300 mg/day of CBD Broad Spectrum Oil
- Placebo oilPlacebo, for comparison
Matched Placebo Oil
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Use of Cannabidiol (CBD) Oil in the Treatment of PTSD: A Placebo-Controlled Randomized Clinical Trial
- Publications
- Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial.Contemporary clinical trials, 2022
- Record updated
- 22 November 2023